Rheopheresis for age-related macular degeneration: Clinical results and putative mechanism of action

Canadian Journal of Ophthalmology

Volumn 40, Issue 3, 2005, Pages 332-340

  Pulido, Jose S ^a   Sanders, Donald ^b   Klingel, Reinhard ^c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c Apheresis Research Institute   (Germany)

Author keywords

Age factor; Macular degeneration; Rheopheresis

Indexed keywords

ALPHA 2 MACROGLOBULIN; ANGIOGENIC FACTOR; ANTIOXIDANT; C REACTIVE PROTEIN; COMPLEMENT; COMPLEMENT FACTOR H; FIBRINOGEN; FIBRONECTIN; FIBULIN; FREE RADICAL; HEPARIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METALLOPROTEINASE; PIGMENT EPITHELIUM DERIVED FACTOR; PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; VASCULOTROPIN; VITAMIN; VITRONECTIN; VON WILLEBRAND FACTOR;

BRUCH MEMBRANE; CLINICAL TRIAL; ELECTRORETINOGRAPHY; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; PATHOPHYSIOLOGY; PIGMENT EPITHELIUM; PLASMAPHERESIS; POLYMERASE CHAIN REACTION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHEOPHERESIS; RISK; SAFETY; VISUAL ACUITY;

EID: 21744436076     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/S0008-4182(05)80076-6     Document Type: Article

References (37)

1. Klingel R, Fassbender C, Fassbender T, Göhlen B. Clinical studies to implement rheopheresis for age-related macular degeneration guided by evidence-based medicine. Transfus Apheresis Sci 2003;29:71-84.
2. Brunner R, Widder RA, Walter P, Lüke C, Godehardt E, Bartz-Schmidt KU, et al. Influence of membrane differential filtration on the natural course of age-related macular degeneration - a randomized trial. Retina 2000;20:483-91.
3. Suckfüll M, for the Hearing Loss Study Group. Fibrinogen and LDL-apheresis in treatment of sudden hearing loss: a randomized multicentre trial. Lancet 2002;360:1811-7.
4. Knupp C, Chong NH, Munro PM, Luthert PJ, Squire JM. Analysis of the collagen VI assemblies associated with Sorsby's fundus dystrophy. J Struct Biol 2002;137:31-40.
5. Weber BH, Vogt G, Pruett RG, Stohr H, Felbor U. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP-3) in patients with Sorsby's fundus dystrophy. Nat Genet 1994;8:352-6.
6. Klenotic PA, Munier FL, Marmorstein LY, Anand-Apte B. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1). J Biol Chem 2004;279:30469-73.
7. Soboleva G, Geis B, Schrewe H, Weber BH, Sorsby fundus dystrophy mutation TIMP3(S156C) affects the morphological and biochemical phenotype but not metalloproteinase homeostasis. J Cell Physiol 2003;197:149-56.
8. Hageman GS, Luthert PJ, Chong NHV, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in ageing and age-related macular degeneration. Prog Retin Eye Res 2001;20:705-32.
9. Preissner KT, Pötsch B. Vessel wall-dependent metabolic pathways of the adhesive proteins von-Willebrand factor and vitronectin. Histol Histopathol 1995;10:239-51.
10. Stockmann A, Hess S, Declerck P, Timpl R, Preissner KT. Multimeric vitronectin. J Biol Chem 1993;268:22874-82.
11. Stone EM, Braun TA, Russell SR, Kuehn MH, Lotery AJ, Moore PA, et al. Missense variations in the fibulin 5 gene and age-related macular degeneration. N Engl J Med 2004;351: 346-53.
12. Gu X, Meer SG, Miyagi M, Rayborn MF, Hollyfield JG, Crabb JW. Garboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. J Biol Chem 2003;278:42027-35.
13. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no, 8. Arch Ophthalmol 2001;119:1417-36.
14. Ida H, Ishibashi K, Reiser K, Hjelmeland LM, Handa JT. Ultrastructural aging of the RPE-Bruch's membrane-choriocapillaris complex in the D-galactose-treated mouse. Invest Ophthalmol Vis Sci 2004;45:2348-54.
15. Pulido JS. Experimental nonenzymatic glycosylation of vitreous collagens occurs by two pathways. Trans Am Opthalmol Soc 1996;94:1029-72.
16. Suter M, Reme C, Grimm C, Wenzel A, Jaattela M, Esser P, et al. Age-related macular degeneration. The lipofuscin component N-retinyl-N- retinylidene ethanolamine detaches proapoptotic proteins from mitochondria and induces apoptosis in mammalian retinal pigment epithelial cells. J Biol Chem 2000;275:39625-30.
17. Storkebaum E, Lambrechts D, Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 2004;26:943-54.
18. Friedman E. A hemodynamic model of the pathogenesis of age-related macular degeneration. Am J Ophthalmol 1997; 124:677-82.
19. Chen SJ, Cheng CY, Lee AF, Lee FL, Chou JCK, Hsu WM, et al. Pulsatile ocular blood flow in asymmetric exudarive age related macular degeneration. Br J Ophthalmol 2001;85: 1411-5.
20. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004;122: 598-614.
21. Klingel R, Mumme C, Fassbender T, Himmelsbach F, Altes U, Lotz J, et al. Rheopheresis in patients with ischemic diabetic foot syndrome: results of an open label prospective pilot trial. Ther Apher Dial 2003;7:444-55.
22. Tamai M, Mizuno K, Chader GJ. In vitro studies on shedding and phagocytosis of rod outer segments in the rat retina: effect of oxygen concentration. Invest Ophthalmol 1982;22: 439-48.
23. Moore DJ, Clover GM. The effect of age on the macromolecular permeability of human Bruchs membrane. Invest Ophthalmol Vis Sci 2001;42:2970-5.
24. Ciulla TA, Harris A, Martin BJ. Ocular perfusion and age-related macular degeneration. Acta Ophthalmol Scand 2001;79:108-15.
25. Hussain AA, Rowe L, Marshall J. Age-related alterations in the diffusional transport of amino acids across the human Bruch's-choroid complex. J Opt Soc Am A Opt Image Sci Vis 2002;19:166-72.
26. King GL, Suzuma K. Pigment-epithelium-derived factor - a key coordinator of retinal neuronal and vascular functions. N Engl J Med 2000;342:349-51.
27. Lip PL, Blann AD, Hope-Ross M, Gibson JM, Lip GYH. Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction. Ophthalmology 2001;108:705-10.
28. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science 2005;308:421-4 [published online 2005 Mar 10]. Available: www.sciencemag. org/cgi/content/abstract/1110189 (accessed 2005 Mar 10).
29. Dragon-Durey MA, Frémeaux-Bacchi V, Loirat C, Blouin J, Niaudet P, Deschenes G, et al. Heterozygous and homozygous factor H deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol 2004;15:787-95.
30. Batioglu F, Muftuoglu O, Atmaca L. Optical coherence tomography of fundus abnormalities associated with type II membranoproliferative glomerulonephritis. Retina 2003;23: 261-2.
31. Seddon JM, Gensler G, Milton RC, Klein ML, Rifai N. Association between C-reactive protein and age-related macular degeneration. JAMA 2004;291:704-10.
32. Widder RA, Farvili E, Reis RGJ, Lüke C, Walter P, Kirchhof B, et al. The treatment of age-related macular degeneration (ARMD) with extracorporeal treatment procedures. A follow-up of four years [abstract]. Invest Ophthalmol Vis Sci 2002;43:2906.
33. Brunner R, Widder RA, Fischer RA, Walter P, Bartz-Schmidt KU, Heimann K. Clinical efficacy of haemorheological treatment using plasma exchange, selective adsorption and membrane differential filtration in maculopathy, retinal vein occlusion and uveal effusion syndrome. Transfus Sci 1996;17: 493-8.
34. Soudavar F, Widder RA, Brunner R, Walter P, Bartz-Schmitz KU, Borberg H, et al. Changes of retinal haemodynamics after elimination of high molecular weight proteins and lipids in patients with age-related macular degeneration [abstract]. Invest Ophthalmol Vis Sci 1998;39:386.
35. Brunner R, Widder RA, Writer P, Borberg H, Oette K. Change in hemorheological and biochemical parameters following membrane differential filtration. Int J Artif Organs 1995;18:794-8.
36. Swartz M, Rabetoy G. Treatment of non-exudative age-related macular degeneration using membrane differential filtration apheresis [abstract]. Invest Ophthalmol Vis Sci 1999;40:319.
37. Pulido JS; Multicenter Investigation of Rheopheresis for AMD (MIRA-1) Study Group. Multicenter prospective, randomized, double-masked, placebo-controlled study of rheopheresis to treat nonexudative age-related macular degeneration: interim analysis. Trans Am Ophthalmol Soc 2002;100:85-106.